Loading…

The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature

Abstract Introduction Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this prot...

Full description

Saved in:
Bibliographic Details
Published in:Military medicine 2019-03, Vol.184 (Supplement_1), p.78-82
Main Authors: Glick, Yuval, Furer, Ariel, Glick, Karina, Yitzhak, Avraham, Brosh, Tal
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13
cites cdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13
container_end_page 82
container_issue Supplement_1
container_start_page 78
container_title Military medicine
container_volume 184
creator Glick, Yuval
Furer, Ariel
Glick, Karina
Yitzhak, Avraham
Brosh, Tal
description Abstract Introduction Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature. Methods We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols. Results Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features. Conclusion Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.
doi_str_mv 10.1093/milmed/usy292
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2196515813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/milmed/usy292</oup_id><sourcerecordid>2196515813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</originalsourceid><addsrcrecordid>eNqFkUtLAzEUhYMoWqtLtxJw42Y0j3llWeqrULRIBXdDMnMHU2YmNckoxY3_wX_oLzFSpeDG1b0cPs493IPQESVnlAh-3uqmheq8dysm2BYaUMFJlFL-uI0GhLA0ikmW7KF95xaE0FjkdBftcSLCzvMBeps_AZ44K6HR-AJq6BzgK2NLcHhmdOexqfGkW_R2hUed160urVFaNnhuQfoWAjGzxpvSNPjz_QOP8C28biTZVfgeXnTQgpEPx6bag5W-t3CAdmrZODj8mUP0cHU5H99E07vryXg0jUouuI-qhOUsU4KmRMU5pCpRKhN5mUEmS054XIVZc8ZyVXFJaVJntaCiqpgSkijKh-h07bu05rkH54tWuxKaRnZgelcwKtKEJjnlAT35gy5Mb7uQrmAxJ5SQPIsDFa2p8AvnLNTF0upW2lVBSfHdSrFupVi3EvjjH9defcu_9G8Nm4SmX_7j9QVzFJlM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430100874</pqid></control><display><type>article</type><title>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</title><source>Oxford Journals Online</source><creator>Glick, Yuval ; Furer, Ariel ; Glick, Karina ; Yitzhak, Avraham ; Brosh, Tal</creator><creatorcontrib>Glick, Yuval ; Furer, Ariel ; Glick, Karina ; Yitzhak, Avraham ; Brosh, Tal</creatorcontrib><description>Abstract Introduction Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature. Methods We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols. Results Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features. Conclusion Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.</description><identifier>ISSN: 0026-4075</identifier><identifier>EISSN: 1930-613X</identifier><identifier>DOI: 10.1093/milmed/usy292</identifier><identifier>PMID: 30901438</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; Guidelines as Topic ; Humans ; Israel ; Military Medicine - trends ; Point-of-Care Systems - trends ; Protocol ; Trauma ; Wounds and Injuries - drug therapy</subject><ispartof>Military medicine, 2019-03, Vol.184 (Supplement_1), p.78-82</ispartof><rights>Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2019</rights><rights>Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</citedby><cites>FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30901438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glick, Yuval</creatorcontrib><creatorcontrib>Furer, Ariel</creatorcontrib><creatorcontrib>Glick, Karina</creatorcontrib><creatorcontrib>Yitzhak, Avraham</creatorcontrib><creatorcontrib>Brosh, Tal</creatorcontrib><title>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</title><title>Military medicine</title><addtitle>Mil Med</addtitle><description>Abstract Introduction Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature. Methods We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols. Results Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features. Conclusion Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Guidelines as Topic</subject><subject>Humans</subject><subject>Israel</subject><subject>Military Medicine - trends</subject><subject>Point-of-Care Systems - trends</subject><subject>Protocol</subject><subject>Trauma</subject><subject>Wounds and Injuries - drug therapy</subject><issn>0026-4075</issn><issn>1930-613X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkUtLAzEUhYMoWqtLtxJw42Y0j3llWeqrULRIBXdDMnMHU2YmNckoxY3_wX_oLzFSpeDG1b0cPs493IPQESVnlAh-3uqmheq8dysm2BYaUMFJlFL-uI0GhLA0ikmW7KF95xaE0FjkdBftcSLCzvMBeps_AZ44K6HR-AJq6BzgK2NLcHhmdOexqfGkW_R2hUed160urVFaNnhuQfoWAjGzxpvSNPjz_QOP8C28biTZVfgeXnTQgpEPx6bag5W-t3CAdmrZODj8mUP0cHU5H99E07vryXg0jUouuI-qhOUsU4KmRMU5pCpRKhN5mUEmS054XIVZc8ZyVXFJaVJntaCiqpgSkijKh-h07bu05rkH54tWuxKaRnZgelcwKtKEJjnlAT35gy5Mb7uQrmAxJ5SQPIsDFa2p8AvnLNTF0upW2lVBSfHdSrFupVi3EvjjH9defcu_9G8Nm4SmX_7j9QVzFJlM</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Glick, Yuval</creator><creator>Furer, Ariel</creator><creator>Glick, Karina</creator><creator>Yitzhak, Avraham</creator><creator>Brosh, Tal</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</title><author>Glick, Yuval ; Furer, Ariel ; Glick, Karina ; Yitzhak, Avraham ; Brosh, Tal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Guidelines as Topic</topic><topic>Humans</topic><topic>Israel</topic><topic>Military Medicine - trends</topic><topic>Point-of-Care Systems - trends</topic><topic>Protocol</topic><topic>Trauma</topic><topic>Wounds and Injuries - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glick, Yuval</creatorcontrib><creatorcontrib>Furer, Ariel</creatorcontrib><creatorcontrib>Glick, Karina</creatorcontrib><creatorcontrib>Yitzhak, Avraham</creatorcontrib><creatorcontrib>Brosh, Tal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Military medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glick, Yuval</au><au>Furer, Ariel</au><au>Glick, Karina</au><au>Yitzhak, Avraham</au><au>Brosh, Tal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</atitle><jtitle>Military medicine</jtitle><addtitle>Mil Med</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>184</volume><issue>Supplement_1</issue><spage>78</spage><epage>82</epage><pages>78-82</pages><issn>0026-4075</issn><eissn>1930-613X</eissn><abstract>Abstract Introduction Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature. Methods We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols. Results Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features. Conclusion Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30901438</pmid><doi>10.1093/milmed/usy292</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0026-4075
ispartof Military medicine, 2019-03, Vol.184 (Supplement_1), p.78-82
issn 0026-4075
1930-613X
language eng
recordid cdi_proquest_miscellaneous_2196515813
source Oxford Journals Online
subjects Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobial agents
Guidelines as Topic
Humans
Israel
Military Medicine - trends
Point-of-Care Systems - trends
Protocol
Trauma
Wounds and Injuries - drug therapy
title The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A47%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Israeli%20Defense%20Forces%20Point%20of%20Injury%20Antimicrobial%20Treatment%20Protocol%20%E2%80%93%20A%20New%20Protocol%20and%20Review%20of%20the%20Literature&rft.jtitle=Military%20medicine&rft.au=Glick,%20Yuval&rft.date=2019-03-01&rft.volume=184&rft.issue=Supplement_1&rft.spage=78&rft.epage=82&rft.pages=78-82&rft.issn=0026-4075&rft.eissn=1930-613X&rft_id=info:doi/10.1093/milmed/usy292&rft_dat=%3Cproquest_cross%3E2196515813%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2430100874&rft_id=info:pmid/30901438&rft_oup_id=10.1093/milmed/usy292&rfr_iscdi=true